Real-World Effectiveness of Osimertinib in Non-Small Cell Lung Cancer (NSCLC) with EGFR Mutation: Systematic Review and Meta-Analysis


Almutairi A1, Alkhatib N2, Maghaireh M2, Halloush S3, Rashdan O4, Manasrah A5, Abraham I6, Almaaytah A7, Abumansour H2, Saleh M8, Khassawaneh A9
1Saudi Food and Drug Authority, Riyadh , Saudi Arabia, 2Al-Zaytoonah University, Amman, Jordan, 3Applied Science Private University, Amman, Jordan, 4Middle East University of Jordan, Amman, Jordan, 5Yarmouk University, Louisville , KY, USA, 6University of Arizona, Tucson, AZ, USA, 7Jordan University of Science and Technology, Irbid, Jordan, 8The University of Jordan, Amman, Jordan, 9Yarmouk University, Irbid, Jordan

Presentation Documents

OBJECTIVES: Osimertinib has been lunched in 2018 as an innovative tyrosine kinase inhibitor in the treatment of non-small cell lung cancer (NSCLC) that targets T790M mutations. The assessment of real-world effectiveness of osimertinib is lacking. This study aims to evaluate the real-world effectiveness of osimertinib in NSCLC.

METHODS: PubMed MEDLINE, Elsevier EMBASE, Cochrane Library and Google Scholar were systematically reviewed to collect real-world data on overall response rate (ORR), disease control rates (DCR), complete response (CR), partial response (PR), stable disease (SD), progressive disease PD); comparative hazard ratios for overall survival (OSHR) and progression-free survival (PFSHR); and AEs grade ≥3. A meta-analyses were performed for quantitatively estimated outcomes in single arm studies that assessed osimertinib and in two arms if osimertinib was compared to other alternatives. The study was conducted based on the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. Moreover, the study protocol was registered in the International Prospective Register of Systematic Reviews. The approval identification code is CRD42022328280.

RESULTS: In this study, 46 observational studies were included. Osimertinib showed an ORR of 57.3%(95%CI=52.6%, 61.9%); CR rate of 2.8%(95%CI=2.0%, 3.90%); PR rate of 55.3%(95%CI=49.9%, 60.6%); SD rate of 24.7%(95%CI=24.1%, 31.6%); PD rate of 9.1%(95%CI=6.0%, 13.6%). Osimertinib showed significant superiority over afatinib in terms overall survival and progression-free survival in T790M+ population; the OSHR was 0.60(95%CI=0.42, 0.86, P value=0.006); the PFSHR was 0.70(95%CI=0.53, 0.94, P value=0.016). The rate of occurrence of the most common AEs grade ≥3 was QT prolongation and was less than 2 percent among the included study population.

CONCLUSIONS: In general NSCLC population with T790M mutations, osimertinib was reasonably effective and safe. In terms of OSHR and PFHR, osimertinib was statistically superior over afatinib in NSCLC patients with T790 mutations.

Conference/Value in Health Info

2023-05, ISPOR 2023, Boston, MA, USA

Value in Health, Volume 26, Issue 6, S2 (June 2023)




Study Approaches

Topic Subcategory

Meta-Analysis & Indirect Comparisons


Drugs, Oncology

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now